Indeed, EGFR itself is the target of several therapeutics: either RTK inhibitors such as gefitinib, used in lung cancer, or monoclonal antibody inhibitors such as cetuximab, employed against colon cancer (118). Here, EGFR is linked to lung carcinoma.